Stocktoria
LENSAR, Inc. LNSR
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-09-21
LENSAR, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $58.4M | $53.5M | $42.2M | $35.4M | $34.5M | $26.4M | $30.5M |
| R&D expense | $5.6M | $5.3M | $6.1M | $11.8M | $12.4M | $7.6M | $7.6M |
| SG&A expense | $45.2M | $26.5M | $26.1M | $27.2M | $23.9M | $23.8M | $17.1M |
| Operating income | -$24.6M | -$10.7M | -$12.2M | -$20.2M | -$19.7M | -$18.5M | -$12.7M |
| Interest expense | — | — | — | — | — | $1.3M | $2.0M |
| Net income | -$34.3M | -$31.4M | -$14.4M | -$19.9M | -$19.6M | -$19.8M | -$14.7M |
| EPS (diluted) | $-2.87 | $-2.73 | $-1.31 | $-1.96 | $-2.09 | — | — |
| Operating cash flow | -$14.8M | -$2.3M | -$9.7M | -$14.9M | -$9.0M | -$13.8M | -$12.6M |
| Free cash flow | -$14.9M | -$2.4M | -$9.9M | -$15.0M | -$9.3M | -$14.2M | -$13.0M |
| Cash & equivalents | $13.0M | $16.3M | $20.6M | $14.7M | $31.6M | $40.6M | $4.6M |
| Inventory | $21.5M | $11.4M | $15.7M | $11.7M | $6.5M | $13.5M | $8.1M |
| Total assets | $71.4M | $66.3M | $69.6M | $55.8M | $66.5M | $79.1M | $34.5M |
| Total liabilities | $83.7M | $47.7M | $22.4M | $13.9M | $11.6M | $11.9M | $65.1M |
| Shareholders' equity | -$26.0M | $4.9M | $33.4M | $42.0M | $54.9M | $67.2M | -$30.6M |
Growth · year-over-year · Revenue CAGR 11.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +9.2% | +26.9% | +19.2% | +2.6% | +30.6% | -13.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.